Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 11:22:102-104.
doi: 10.1016/j.ijcha.2018.12.009. eCollection 2019 Mar.

Hospitalization cost reduction with sacubitril-valsartan implementation in a cohort of patients from the Daunia Heart Failure Registry

Michele Correale  1 , Ilenia Monaco  1 , Armando Ferraretti  1 , Lucia Tricarico  1 , Giuseppina Padovano  1 , Ennio Sascia Formica  1 , Valeria Tozzi  1 , Davide Grazioli  2 , Matteo Di Biase  3 , Natale Daniele Brunetti  1
Affiliations

Hospitalization cost reduction with sacubitril-valsartan implementation in a cohort of patients from the Daunia Heart Failure Registry

Michele Correale et al. Int J Cardiol Heart Vasc. .

Abstract

Introduction: Aim of this study was to assess the impact of the introduction of new class of drugs (ARNI: angiotensin receptor-neprilysin inhibitor) on hospital related costs in a real world cohort of patients with chronic heart failure (CHF).

Methods: Seventy-three consecutive patients with CHF and systolic dysfunction eligible for the treatment with ARNIs from the Daunia Heart Failure Registry were enrolled. Incidence of hospitalizations before and after treatment with ARNI, costs for drug and hospitalization for HF were recorded, indexed per year and compared.

Results: Indexed mean number of hospitalizations per year was 0.93 ± 1.70 before and 0.19 ± 0.70 after introduction of ARNI (p < 0.001, -80%), 2.26 ± 1.95 before and 0.38 ± 1.2 after ARNI in the subgroup of patients with at least one hospitalization for HF in the year before treatment with ARNI (p < 0.001, -83%).Mean indexed cost for hospitalization was 2067 ± 3715 euros before and 1847 ± 1549 after ARNI (p n.s., -11%); in the subgroup with at least one hospitalization for HF 5175 ± 4345 before and 2311 ± 2308 after ARNI (p < 0.001, -55%). Cost reduction increased with the number of indexed hospitalization per year before ARNI from 11% to 66%.

Conclusion: In a real world scenario, treatment with ARNI is associated with lower indexed rates of hospitalizations and hospitalization related costs. Cost reduction increases with at least one indexed hospitalization for heart failure before treatment with ARNI.

Keywords: ARNI; Angiotensin receptor blockers; Chronic heart failure; Cost analysis; Neprilysin inhibition; Sacubitril.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Number of indexed hospitalizations for heart failure before and after treatment with ARNI (p < 0.001): left, whole population; right, patients with at least one indexed hospitalization for heart failure in the year before treatment.
Fig. 2
Fig. 2
Mean indexed costs for hospitalizations for heart failure before and after treatment with ARNI: left, whole population (p n.s.); right, patients with at least one indexed hospitalization for heart failure in the year before treatment (p < 0.001).
Fig. 3
Fig. 3
Relative cost reduction according to number of indexed hospitalization for heart failure before treatment with ARNI.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ponikowski P., Anker S.D., AlHabib K.F., Cowie M.R., Force T.L., Hu S., Jaarsma T., Krum H., Rastogi V., Rohde L.E., Samal U.C., Shimokawa H., Budi Siswanto B., Sliwa K., Filippatos G. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1:4–25. - PubMed
    1. Liao L., Allen L.A., Whellan D.J. Economic burden of heart failure in the elderly. PharmacoEconomics. 2008;26:447–462. - PubMed
    1. Roger Véronique L. Epidemiology of heart failure. Circ. Res. 2013;113:646–659. - PMC - PubMed
    1. Rich Michael W. Cost-effectiveness analysis in clinical practice — the case of heart failure. Arch. Intern. Med. 1999;159:1690–1700. - PubMed
    1. Mantovani L.G., Cortesi P.A., Senni M., Deschaseaux, Haroun R., Pitotti C. Cost-effectiveness of sacubitril/valsartan for heart failure patients with reduced ejection fraction in Italy. Value Health. 2016;19:A650.